

Lexaria Bioscience Corp.  
Form 8-K  
June 20, 2018

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **June 19, 2018**

**LEXARIA BIOSCIENCE CORP.**

(Exact name of registrant as specified in its charter)

<b><u>Nevada</u></b> (State or other jurisdiction of incorporation)	<b><u>000-52138</u></b> (Commission File Number)	<b><u>20-2000871</u></b> (IRS Employer Identification No.)
---	---	--

<b><u>156 Valleyview Road, Kelowna, BC Canada</u></b> (Address of principal executive offices)	<b><u>V1X 3M4</u></b> (Zip Code)
---	-------------------------------------

Registrant's telephone number, including area code **(250) 765-6424**

**N/A**  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 3.02      Unregistered Sales of Equity Securities**

Lexaria has received US\$30,000 from the exercise of 50,000 warrants at the price of US\$0.60, previously granted to third parties who are neither officers nor directors of the Company. In addition, Lexaria has received US\$63,000 from the exercise of 450,000 warrants at the price of US\$0.14, previously granted to an officer of the Company. Lexaria has also received US\$22,500 from the exercise of 247,500 stock options at the price of US\$0.091, previously granted to an officer of the Company.

---

No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.

**The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.**

**Item 7.01 Regulation FD Disclosure**

A copy of the news releases announcing that Lexaria has received US\$115,250 from the exercise of warrants and options previously granted is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.

**Item 9.01 Financial Statements and Exhibits**

99.1 Press Release dated June 19, 2018

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LEXARIA BIOSCIENCE CORP.**

*/s/ Chris Bunka*

**Chris Bunka**

CEO, Principal Executive Officer

Date: June 20, 2018

---